The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety
Abstract
Abstract: The anxiolytic properties of nabilone, a synthetic cannabinoid resembling the natural cannabinoids, were studied in 25 outpatients suffering from anxiety. The drug was compared with a placebo in a double‐blind manner over a 28‐day treatment period. Patients were seen weekly by the physician and were rated by the Hamilton Rating Scale for Anxiety and the Patient's Global Evaluation as well as by patient‐rated evaluations. The results of the study showed a dramatic improvement in anxiety in the nabilone group when compared with placebo ( P < 0.001). Side effects reported were dry mouth, dry eyes, and drowsiness. Patients did not report any of the subjective “altered state” experience of marihuana.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nabilone is a synthetic cannabinoid CB1-receptor agonist (licensed in Canada since 1981 for chemotherapy-induced vomiting and nausea); it is well-tolerated and has a good safety profile [22, 23].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [22]
In the citing paper
“studies in controlled clinical settings confirm that administration of synthetic variants of delta-9-tetrahydrocannabinol (THC), the psychoactive constituent of cannabis, can reduce anxiety in patients with anxiety disorders [7,8]”
From Amygdala FAAH and anandamide: mediating protection and recovery from stress (2013) · cites this paper as [7]
Citations
Cites
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 350
Clinical pharmacology of nabilone, a cannabinol derivative
Lemberger, L., & Rowe, H. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975186720 · Cited by 74
Nakano, S., Gillespie, H. K., & Hollister, L. E. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197823154 · Cited by 59
Single‐Dose Study of Nabilone in Anxious Volunteers
Glass, R. M., UHLENHUTH, E. H., Hartel, F. W., Schuster, C. R., & Fischman, M. W. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02618.x · Cited by 45
Does marijuana enhance experimentally induced anxiety?
Pillard, R. C., McNair, D. M., & Fisher, S. (1974) · Psychopharmacology · doi:10.1007/bf00429414 · Cited by 30
Changes in Anxiety Feelings Following Marihuana Smoking
Abel, E. L. (1971) · British Journal of Addiction to Alcohol & Other Drugs · doi:10.1111/j.1360-0443.1971.tb02384.x · Cited by 25
McLendon, D. M., Harris, R. T., & Maule, W. F. (1976) · Psychopharmacology · doi:10.1007/bf00430486 · Cited by 13
Self-citation
Research works printed but not linked: 4
- Braude MC, 1975, International Conference on the Pharmacology of Cannabis.
- Stark P, 1975, Preclinical pharmacologic profile of psychoactive cannabinoid, Pharmacologist., 17, 210
- Fabre L, 1978, Nabilone, a cannabinoid, in the treatment of anxiety: an open‐label and double‐blind study, Curr Therap Res., 24, 161
- Ilaria R, 1978, Nabilone: a cannabinol derivative in anxiety neurosis, Fed Proc., 37, 6
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Interneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Metadata
- Authors
- FABRE, L. F., & McLENDON, D.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1981-08-09
- Volume
- 21
- Issue
- S1
- Pages
- 377S-382S
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2140255682
- Cited by
- 138
- References
- 7
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 13 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- nabilone, synthetic cannabinoids, anxiety, anxiolytic efficacy, drug safety, placebo comparison, adverse effects, xerostomia, sleepiness, cannabis
- MeSH terms
- Adolescent, Adult, Anxiety Disorders, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Dronabinol, Time Factors, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
